Skip to main content
. 2021 Jan 25;9(2):88. doi: 10.3390/vaccines9020088

Figure 1.

Figure 1

Correlation of CMV-specific ELISpot responses of the T-Track CMV (Lophius Biosciences) and of the T-SPOT.CMV (Oxford Immunotec). This analysis included all pairs of data sets (parallel tests with T-Track CMV and T-SPOT.CMV) in liver transplant recipients (50 at the end of prophylaxis and 49–50 at month 1 thereafter), as also shown in Table 2. Panel (a) shows interferon-γ responses to CMV IE-1 antigens (n = 100) and panel (b) to CMV pp65 antigens (n = 99). At both time points, six out of 56 patients were not tested in parallel. The bold, continuous line indicates the regression line, the dashed lines the 95% confidence interval. SFU—spot forming units.